Doctors at Massachusetts General Hospital in Boston have achieved a milestone in medical history by successfully transplanting a kidney from a genetically modified pig into a 62-year-old man named Richard Slayman, who was suffering from end-stage renal disease.
The surgery, which took place on March 16, marks a significant advancement in the field of organ transplantation, offering hope for patients facing long waits for human organs.
Richard Slayman, a resident of Weymouth, Massachusetts, is reported to be recovering well following the four-hour surgery. This achievement signifies a breakthrough in providing more readily available organs to patients in need.
The kidney used in the transplantation was sourced from eGenesis, a company based in Cambridge, Massachusetts, specializing in genetically editing pigs to remove genes harmful to human recipients and enhance compatibility by adding certain human genes. The company also inactivated viruses inherent to pigs that have the potential to infect humans.
The transplantation utilized an experimental antibody called tegoprubart, developed by Eledon Pharmaceuticals, to help prevent rejection of the pig organ by the patient’s immune system. This underscores the importance of innovative approaches in addressing immune rejection, a significant challenge in xenotransplantation.
Dr. Jim Kim, director of kidney and pancreas transplantation at the USC Transplant Institute, highlighted the considerable interest among experts in the long-term outcomes of this groundbreaking animal-to-human transplant. Previous studies on similar procedures involving kidneys from genetically modified pigs transplanted into monkeys have shown promising results, with survival periods ranging from an average of 176 days to over two years.
While previous attempts, such as the University of Maryland’s transplant of a genetically modified pig heart into a terminally ill patient in January 2022, have faced challenges, the successful kidney transplant represents a major step forward in addressing the organ shortage crisis. Transplant centers are eagerly awaiting authorization from the FDA to conduct clinical trials, which will provide further insights into optimizing treatments for patients on waiting lists.
